95 related articles for article (PubMed ID: 3751461)
1. Pharmacokinetics in the human of a new synthetic vasopressin and oxytocin uterine antagonist.
Lundin S; Akerlund M; Fagerström PO; Hauksson A; Melin P
Acta Endocrinol (Copenh); 1986 Aug; 112(4):465-72. PubMed ID: 3751461
[TBL] [Abstract][Full Text] [Related]
2. Vasotocin analogues which competitively inhibit vasopressin stimulated uterine activity in healthy women.
Akerlund M; Hauksson A; Lundin S; Melin P; Trojnar J
Br J Obstet Gynaecol; 1986 Jan; 93(1):22-7. PubMed ID: 3942702
[TBL] [Abstract][Full Text] [Related]
3. The effect on the human uterus of two newly developed competitive inhibitors of oxytocin and vasopressin.
Akerlund M; Carlsson AM; Melin P; Trojnar J
Acta Obstet Gynecol Scand; 1985; 64(6):499-504. PubMed ID: 4061066
[TBL] [Abstract][Full Text] [Related]
4. Potential use of oxytocin and vasopressin V1a antagonists in the treatment of preterm labour and primary dysmenorrhoea.
Akerlund M; Melin P; Maggi M
Adv Exp Med Biol; 1995; 395():595-600. PubMed ID: 8714023
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics of the oxytocin antagonist atosiban in pregnant women with preterm uterine contractions.
Goodwin TM; Millar L; North L; Abrams LS; Weglein RC; Holland ML
Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):913-7. PubMed ID: 7573268
[TBL] [Abstract][Full Text] [Related]
6. Can primary dysmenorrhea be alleviated by a vasopressin antagonist? Results of a pilot study.
Akerlund M
Acta Obstet Gynecol Scand; 1987; 66(5):459-61. PubMed ID: 3321865
[TBL] [Abstract][Full Text] [Related]
7. Effects of a tocolytic oxytocin analogue on lipid and carbohydrate metabolism.
Eriksson H; Björgell P; Akerlund M; Hauksson A; Melin P
Gynecol Obstet Invest; 1990; 29(2):97-100. PubMed ID: 2335316
[TBL] [Abstract][Full Text] [Related]
8. Uterine blood flow and myometrial activity at menstruation, and the action of vasopressin and a synthetic antagonist.
Hauksson A; Akerlund M; Melin P
Br J Obstet Gynaecol; 1988 Sep; 95(9):898-904. PubMed ID: 3191063
[TBL] [Abstract][Full Text] [Related]
9. Effect of the oxytocin antagonist atosiban (1-deamino-2-D-tyr(OET)-4-thr-8-orn-vasotocin/oxytocin) on nocturanl myometrial contractions, maternal cardiovascular function, transplacental passage, and fetal oxygenation in the pregnant baboon during the last third of gestation.
Nathanielsz PW; Honnebier MB; Mecenas C; Jenkins SL; Holland ML; Demarest K
Biol Reprod; 1997 Aug; 57(2):320-4. PubMed ID: 9241045
[TBL] [Abstract][Full Text] [Related]
10. Receptors for and myometrial responses to oxytocin and vasopressin in preterm and term human pregnancy: effects of the oxytocin antagonist atosiban.
Bossmar T; Akerlund M; Fantoni G; Szamatowicz J; Melin P; Maggi M
Am J Obstet Gynecol; 1994 Dec; 171(6):1634-42. PubMed ID: 7802081
[TBL] [Abstract][Full Text] [Related]
11. Effects of a vasopressin antagonist in women with dysmenorrhea.
Valentin L; Sladkevicius P; Kindahl H; Broeders A; Marsal K; Melin P
Gynecol Obstet Invest; 2000; 50(3):170-7. PubMed ID: 11014949
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic properties of the tocolytic agent [Mpa1, D-Tyr(Et)2, Thr4, Orn8]-oxytocin (antocin) in healthy volunteers.
Lundin S; Broeders A; Melin P
Clin Endocrinol (Oxf); 1993 Sep; 39(3):369-74. PubMed ID: 8222299
[TBL] [Abstract][Full Text] [Related]
13. Plasma half-lives of vasopressin and oxytocin analogs after iv injection in rats.
Gazis D
Proc Soc Exp Biol Med; 1978 Sep; 158(4):663-5. PubMed ID: 693485
[No Abstract] [Full Text] [Related]
14. Effect of subcutaneous and intranasal administration of ovine corticotropin-releasing hormone in man: comparison with intravenous administration.
DeBold CR; Sheldon WR; DeCherney GS; Jackson RV; Nicholson WE; Island DP; Orth DN
J Clin Endocrinol Metab; 1985 May; 60(5):836-40. PubMed ID: 2984233
[TBL] [Abstract][Full Text] [Related]
15. Oxytocin receptor blockade: a new principle in the treatment of preterm labor?
Andersen LF; Lyndrup J; Akerlund M; Melin P
Am J Perinatol; 1989 Apr; 6(2):196-9. PubMed ID: 2540760
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of 1-deamino-[D-Tyr(Oethyl)2, Thr4, Orn8] vasotocin, an oxytocin antagonist, in animal models of uterine contractility and preterm labor: a new tocolytic agent.
Hahn DW; Demarest KT; Ericson E; Homm RE; Capetola RJ; McGuire JL
Am J Obstet Gynecol; 1987 Oct; 157(4 Pt 1):977-82. PubMed ID: 3674173
[TBL] [Abstract][Full Text] [Related]
17. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
Allen A; Down G; Newland A; Reynard K; Rousell V; Salmon E; Scott R
Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability and pharmacokinetics of sublingual oxytocin in male volunteers.
De Groot AN; Vree TB; Hekster YA; Pesman GJ; Sweep FC; Van Dongen PJ; Van Roosmalen J
J Pharm Pharmacol; 1995 Jul; 47(7):571-5. PubMed ID: 8568623
[TBL] [Abstract][Full Text] [Related]
19. Synthetic antagonists of the myometrial response to vasopressin and oxytocin.
Melin P; Trojnar J; Johansson B; Vilhardt H; Akerlund M
J Endocrinol; 1986 Oct; 111(1):125-31. PubMed ID: 3783079
[TBL] [Abstract][Full Text] [Related]
20. Profile of an oxytocin antagonist, RWJ 22164 for treatment of preterm labor in laboratory models of uterine contractility.
Demarest KT; Hahn DW; Ericson E; Capetola RJ; Fuchs AR; McGuire JL
Am J Perinatol; 1989 Apr; 6(2):200-4. PubMed ID: 2712917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
